rivaroxaban

ELAN Trial: Early vs. Later Initiation of DOAC in Acute Ischemic Stroke and Atrial Fibrillation

ELAN Trial Summary Introduction:The ELAN trial aimed to investigate the optimal timing of initiating direct oral anticoagulants (DOACs) in individuals with atrial fibrillation (AF) who had experienced an acute ischemic stroke. The study compared early anticoagulation (initiated within 48 hours … Read More

VOYAGER PAD Trial: Rivaroxaban in PAD after Revascularization

VOYAGER PAD Trial Summary The VOYAGER PAD trial aimed to assess the efficacy and safety of rivaroxaban, a factor Xa inhibitor, in patients with peripheral artery disease (PAD) who had undergone lower-extremity revascularization. Patients with PAD who have undergone revascularization … Read More

AFIRE Trial Summary: Antithrombotics in AFib and CAD

2019 AFIRE TRIAL Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease Multicenter, open-label trial conducted in Japan Objective: To evaluate the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease. 2236 patients 4.14 Inclusion … Read More

MICHELLE Trial Summary: Rivaroxaban for Thromboprophylaxis in Covid-19

2022 MICHELLE TRIAL Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 Pragmatic, open-label, multicentre, randomized controlled trial Objective: To investigate if extended thromboprophylaxis with Rivaroxaban after hospitalization due to COVID-19 decrease rates of venous & arterial thromboembolism … Read More